CN106509917A - Composite prebiotics and application thereof - Google Patents
Composite prebiotics and application thereof Download PDFInfo
- Publication number
- CN106509917A CN106509917A CN201610982920.7A CN201610982920A CN106509917A CN 106509917 A CN106509917 A CN 106509917A CN 201610982920 A CN201610982920 A CN 201610982920A CN 106509917 A CN106509917 A CN 106509917A
- Authority
- CN
- China
- Prior art keywords
- parts
- stachyose
- oligofructose
- prebiotics
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000013406 prebiotics Nutrition 0.000 title claims abstract description 45
- 239000002131 composite material Substances 0.000 title abstract 6
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 claims abstract description 20
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 claims abstract description 19
- 230000002195 synergetic effect Effects 0.000 claims abstract description 10
- 239000000203 mixture Substances 0.000 claims description 11
- 241000186016 Bifidobacterium bifidum Species 0.000 claims description 10
- 241000186660 Lactobacillus Species 0.000 claims description 10
- 241000894006 Bacteria Species 0.000 abstract description 16
- 235000018291 probiotics Nutrition 0.000 abstract description 16
- 239000006041 probiotic Substances 0.000 abstract description 15
- 235000013305 food Nutrition 0.000 abstract description 6
- 239000003814 drug Substances 0.000 abstract description 4
- 230000035755 proliferation Effects 0.000 abstract description 4
- 239000002994 raw material Substances 0.000 abstract description 3
- 241000186000 Bifidobacterium Species 0.000 abstract description 2
- 235000013361 beverage Nutrition 0.000 abstract description 2
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 abstract 2
- 229940107187 fructooligosaccharide Drugs 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 1
- 230000002349 favourable effect Effects 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 230000000529 probiotic effect Effects 0.000 description 12
- 239000000047 product Substances 0.000 description 10
- 238000000855 fermentation Methods 0.000 description 8
- 230000004151 fermentation Effects 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- YTBSYETUWUMLBZ-QWWZWVQMSA-N D-threose Chemical compound OC[C@@H](O)[C@H](O)C=O YTBSYETUWUMLBZ-QWWZWVQMSA-N 0.000 description 6
- 230000000968 intestinal effect Effects 0.000 description 6
- 239000012467 final product Substances 0.000 description 5
- 229920001542 oligosaccharide Polymers 0.000 description 5
- 150000002482 oligosaccharides Chemical class 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 235000013350 formula milk Nutrition 0.000 description 4
- 210000003608 fece Anatomy 0.000 description 3
- 206010059866 Drug resistance Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 229930182830 galactose Natural products 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- AYRXSINWFIIFAE-SCLMCMATSA-N Isomaltose Natural products OC[C@H]1O[C@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)[C@@H](O)[C@@H](O)[C@@H]1O AYRXSINWFIIFAE-SCLMCMATSA-N 0.000 description 1
- 244000199866 Lactobacillus casei Species 0.000 description 1
- 235000013958 Lactobacillus casei Nutrition 0.000 description 1
- 241000186840 Lactobacillus fermentum Species 0.000 description 1
- 206010048723 Multiple-drug resistance Diseases 0.000 description 1
- 235000008098 Oxalis acetosella Nutrition 0.000 description 1
- 241001119522 Paullinia pinnata Species 0.000 description 1
- 235000010240 Paullinia pinnata Nutrition 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 210000001815 ascending colon Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 230000007366 host health Effects 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 229940017800 lactobacillus casei Drugs 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000013588 oral product Substances 0.000 description 1
- 229940023486 oral product Drugs 0.000 description 1
- 230000000505 pernicious effect Effects 0.000 description 1
- 229920000157 polyfructose Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 150000004666 short chain fatty acids Chemical class 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000003538 tetroses Chemical class 0.000 description 1
- 229920001221 xylan Polymers 0.000 description 1
- 150000004823 xylans Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to composite prebiotics. The composite prebiotics consist of 10 parts by weight of stachyose and 1-100 parts by weight of fructo-oligosaccharide. According to the composite prebiotics disclosed by the invention, stachyose is used as a main raw material, and fructo-oligosaccharide is used as an auxiliary material, so that the composite prebiotics can generate a favorable synergistic effect on the proliferation of probiotics (bifidobacteria and bacterium lacticum). The composite prebiotics disclosed by the invention are simple in formula, complete in functions, in synergistic synergy, safe and natural, and can be used as raw materials or ingredients of beverages, health-care foods, common foods, and formula foods and drugs for special medical purposes.
Description
Technical field
The present invention relates to a kind of complex prebiotics, and in particular to one kind is by stachyose and oligofructose（FOS）Compatibility is constituted
Complex prebiotics, while providing the synergistic function that the complex prebiotics are produced to proliferation of probiotics.
Background technology
Prebioticses be lost in a kind of modern diet, the dietary fiber beneficial to health, be that one kind can be selected
Selecting property is fermented and changes constituting and active composition of food to host health profitable strain in gastrointestinal tract.Prebioticses must are fulfilled for
Three conditions：1st, acidproof and hydrolytic enzyme, is not digested and assimilated with small intestinal by stomach；2nd, can be fermented by intestinal microbial population；3rd, can be optionally
The growth of the intestinal beneficial bacterium such as stimulation of bifidobacteria and lactobacilluss.
It is mainly oligosaccharide substance using more prebioticses at present, such as oligomeric galactose, inulin, oligofructose, low
Xylan, oligomeric isomaltose, soybean oligo saccharide, shitosan etc..On Vehicles Collected from Market, prebioticses product is mainly with following three kinds of sides
Formula is present：1st, make an addition in baby milk powder as additive；2nd, produced into symphysis unit with little or minimum dosage and probiotic bacteria compatibility
Product；2nd, the prebioticses product of folk prescription abundance consumption.But, there is following defect in those symphysis units or prebioticses product：
1st, in symphysis unit product, prebioticses addition is too small, it is difficult to reach its minimum action consumption, it is more difficult to play prebioticses
The physiological function that should be played.
2nd, the product such as symphysis unit and probiotic bacteria is not suitable for life-time service.Medical research proves, human body life-time service probiotic bacteria,
The ability that function of intestinal canal can be promoted progressively to lose self-reproduction probioticss, long human body intestinal canal will produce dependency, medically
Referred to as " probiotic bacteria dependence syndrome ".And human body once suffers from " probiotic bacteria dependence syndrome ", throughout one's life all will be by probiotic oral product
Come the health status for sustaining life.In addition, excessive use of probiotic bacteria is likely to become the new hotbed for breeding " superbug ".Due to
Many lactic acid bacterias have multiple drug resistance to antibiotic, through community life, contact with pathogen, it is likely that will be self-contained
Drug resistance gene pass to pathogen, be allowed to obtain Drug resistance and become " superbug ", may can without medicine when causing infection
Doctor.
3rd, folk prescription prebioticses product limitation is big.In due to various oligosaccharides prebioticses, various oligosaccharide have each
Whether and strong and weak different unique individual character e.g., to the facilitation of various probiotic bacterias；To the rejection ability of various pernicious bacterias not
Together；In identical colon ecological environment, the time length of fermentation is different；In fermentation, produced gas flow is different；Fermentation
The species of the short-chain fatty acid produced during decomposition is different with amount；It is different in the Adhering capacity of big intestinal wall；In each region of big enteral
Fermentation activity difference etc. so that folk prescription prebioticses product limitation is big.
The content of the invention
The technical problem to be solved is：For above-mentioned the deficiencies in the prior art, there is provided one kind with stachyose is
Master, the complex prebiotics of compatibility oligofructose and its application.
For solving above-mentioned technical problem, the technical solution adopted in the present invention is：A kind of complex prebiotics, its feature exist
In the complex prebiotics are made up of 10 parts of stachyose and oligofructose 1-100 parts by weight.
Preferably, the complex prebiotics are made up of 10 parts of stachyose and oligofructose 1-50 parts by weight.
Preferably, the complex prebiotics are made up of 10 parts of stachyose and oligofructose 50-100 parts by weight.
It is prepared that above-mentioned complex prebiotics are that water intaking threose is mixed homogeneously with oligofructose.This complex prebiotics can be to probiotic bacteria
（Bacillus bifiduss and lactobacilluss）Propagation produces good synergistic function, specific as follows：
Take 4 parts of CAM culture medium（It is not added with glucose）, it is separately added into distilled water（Blank group）, 1% oligofructose（Oligofructose
Group）, 1% stachyose（Stachyose group）, and 1% product of the present invention（Stachyose+oligofructose group）, make 250ml 4 parts
Sample, sterilizing.Fresh excreta 10g is taken, 200ml normal saline is added, is sufficiently mixed, takes supernatant, take supernatant 1ml respectively and add
Enter in aforesaid 4 parts of samples and cultivate, 37 DEG C of fermentations determine the quantity of bacillus bifiduss and lactobacilluss in fermentation liquid after 24 hours, see figure
1.As a result show:After the compositionss of addition oligofructose, stachyose and stachyose+oligofructose, the bacillus bifiduss in feces
And the quantity of lactobacilluss is improved relative to blank control group, but the propagation quantity of present invention group bacillus bifiduss and lactobacilluss
Apparently higher than stachyose group and oligofructose group, illustrate the prebiotic compositions of the present invention to probiotic bacteria（Bacillus bifiduss and newborn bar
Bacterium）Propagation generate good synergistic function.
Compared with prior art, advantages of the present invention is as follows：
Stachyose is a kind of naturally occurring tetrose, belongs to oligomeric galactose, is not hydrolyzed by human digestive enzymes.With poly-
Right little, water solublity is strong, and fermentation is fast, mainly ferments in ascending colon, has good multiplication capacity to bacillus bifiduss, lactobacilluss etc.,
There is good optimization function to Bacterial community in large intestine.Meanwhile, stachyose has outstanding physiological function：Loosening bowel to relieve constipation, reduces
Blood glucose and blood pressure, adjust blood fat, enhance immunity, adjunct antineoplastic etc..This complex prebiotics is leading with stachyose, to promoting
China's oligosaccharide and prebioticses industry development will produce important strategic importance.
The compound product of composition, has good synergistic function to proliferation of probiotics.The stachyose of folk prescription is low
Polyfructose. is different to different bacillus bifiduss and the proliferation function power that lactobacilluss are produced, and such as oligofructose is by two discriminations in pairs
Bacillus, lactobacillus casei, the availability extreme difference of Lactobacillus fermenti, and stachyose can obtain its good utilization.And stachyose with
Oligofructose compatibility is to probiotic bacteria（Bacillus bifiduss and lactobacilluss）Propagation can produce good synergistic function.
The present invention complex prebiotics formula simplify, multiple functional, Synergistic, safety it is natural, can be used as beverage, health care
The raw material of food, bread and cheese, special medicine purposes formula food or medicine or dispensing are used.
Description of the drawings
Fig. 1 is feces probiotic bacteria after fermentation 24h（Bacillus bifiduss and lactobacilluss）Quantitative comparison schemes.
Specific embodiment
Embodiment 1
1 part of mixing of 10 parts of threose of water intaking and oligofructose by weight, stirs, obtains final product the prebiotic compositions of the present invention.
Embodiment 2
30 parts of 10 parts of threose of water intaking and oligofructose, stir by weight, obtain final product the prebiotic compositions of the present invention.
Embodiment 3
50 parts of 10 parts of threose of water intaking and oligofructose, stir by weight, obtain final product the prebiotic compositions of the present invention.
Embodiment 4
70 parts of 10 parts of threose of water intaking and oligofructose, stir by weight, obtain final product the prebiotic compositions of the present invention.
Embodiment 5
100 parts of 10 parts of threose of water intaking and oligofructose, stir by weight, obtain final product the prebiotic compositions of the present invention.
Claims (5)
1. a kind of complex prebiotics, it is characterised in that the complex prebiotics are by weight by 10 parts and oligofructose 1- of stachyose
100 parts of compositions.
2. a kind of complex prebiotics as claimed in claim 1, it is characterised in that the complex prebiotics are by weight by Herba Stachydis Japonicae
10 parts and oligofructose 1-50 part compositions of sugar.
3. a kind of complex prebiotics as claimed in claim 1, it is characterised in that the complex prebiotics are by weight by Herba Stachydis Japonicae
10 parts and oligofructose 50-100 part compositions of sugar.
4. application of the complex prebiotics described in claim 1 or 2 or 3 in Synergistic bacillus bifiduss propagation.
5. application of the complex prebiotics described in claim 1 or 2 or 3 in Synergistic lactobacilluss propagation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610982920.7A CN106509917A (en) | 2016-11-09 | 2016-11-09 | Composite prebiotics and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610982920.7A CN106509917A (en) | 2016-11-09 | 2016-11-09 | Composite prebiotics and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106509917A true CN106509917A (en) | 2017-03-22 |
Family
ID=58350058
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610982920.7A Pending CN106509917A (en) | 2016-11-09 | 2016-11-09 | Composite prebiotics and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106509917A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107495383A (en) * | 2017-08-14 | 2017-12-22 | 北京市营养源研究所 | One kind relaxes bowel complex prebiotics and preparation method and application |
| CN107927789A (en) * | 2017-12-01 | 2018-04-20 | 刘峰 | A kind of prebiotics food and preparation method thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101268830A (en) * | 2008-04-07 | 2008-09-24 | 江门量子高科生物工程有限公司 | Complex prebiotics |
| CN102266107A (en) * | 2011-08-29 | 2011-12-07 | 胡跃安 | Composite prebiotics beverage and preparation method thereof |
| CN103549612A (en) * | 2013-11-07 | 2014-02-05 | 雷小康 | Drink and preparation method thereof |
| CN104585771A (en) * | 2014-03-06 | 2015-05-06 | 雷小康 | Health-care beverage and preparation method thereof |
-
2016
- 2016-11-09 CN CN201610982920.7A patent/CN106509917A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101268830A (en) * | 2008-04-07 | 2008-09-24 | 江门量子高科生物工程有限公司 | Complex prebiotics |
| CN102266107A (en) * | 2011-08-29 | 2011-12-07 | 胡跃安 | Composite prebiotics beverage and preparation method thereof |
| CN103549612A (en) * | 2013-11-07 | 2014-02-05 | 雷小康 | Drink and preparation method thereof |
| CN104585771A (en) * | 2014-03-06 | 2015-05-06 | 雷小康 | Health-care beverage and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 齐景伟 等: "《反刍动物生物饲料开发与应用》", 31 March 2014, 内蒙古大学出版社 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107495383A (en) * | 2017-08-14 | 2017-12-22 | 北京市营养源研究所 | One kind relaxes bowel complex prebiotics and preparation method and application |
| CN107927789A (en) * | 2017-12-01 | 2018-04-20 | 刘峰 | A kind of prebiotics food and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7273725B2 (en) | Novel bifidobacterium bacterium and composition containing the bacterium | |
| JP5498698B2 (en) | New uses of white jellyfish miscellaneous polysaccharides or their extracts | |
| CN104983746B (en) | Complex probiotics and preparation method thereof | |
| US20100166721A1 (en) | Probotic compositions and uses thereof | |
| US20110165127A1 (en) | Dairy-derived probiotic compositions and uses thereof | |
| CN104206539A (en) | Probiotic-containing infant milk powder | |
| CN107594284A (en) | A kind of solid beverage containing prebiotics and probiotics and preparation method thereof | |
| CN107019701A (en) | The method that the incidence of disease of the necrotizing enterocolitis of baby, child or children is reduced using human milk oligosaccharides | |
| CN104023560A (en) | Human Milk Oligosaccharides For Preventing Injury And/Or Promoting Healing Of The Gastrointestinal Tract | |
| CN101449830B (en) | Mid-aged milk powder added with biostime and preparation method thereof | |
| CN104413334A (en) | Edible composition as well as preparation method and application thereof | |
| CN105722514A (en) | Compositions for use in the prevention or treatment of necrotizing enterocolitis in infants or young children born by C-section | |
| JP2009189374A (en) | New galactooligosaccharide composition and method for preparing the same | |
| CN108740251A (en) | A kind of probiotic gel candy and preparation method thereof improving constipation | |
| CA3017371A1 (en) | Food compositions for weaning | |
| CN106539089A (en) | A kind of complex prebiotics and its application | |
| CN108850397A (en) | A kind of probiotic gel candy and preparation method thereof of only diarrhea | |
| JP7240327B2 (en) | Novel bifidobacterium bacterium and composition containing the bacterium | |
| CN106465829A (en) | Night using type dietary fiber solid beverage and preparation method thereof | |
| CN109561723A (en) | For preventing, treating the alimentation composition and infant formula of the mixture comprising oligosaccharide and optionally bifidobacterium lactis of non-rotavirus induced diarrhea or reduction its severity | |
| CN107668208A (en) | A kind of formula milk for promoting intestinal health | |
| CA2812909C (en) | Compositions and methods for augmenting kidney function | |
| CN106890317A (en) | A kind of lactase composition and its application | |
| Niu et al. | Effect of fructooligosaccharides on the colonization of Lactobacillus rhamnosus AS 1.2466 T in the gut of mice | |
| CN104431352B (en) | A kind of preparation method and application of growth promotion symphysis unit bacterium solution |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170322 |
|
| RJ01 | Rejection of invention patent application after publication |